These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30540837)

  • 1. Penetration of new antidiabetic medications in East Asian countries and the United States: A cross-national comparative study.
    Kubota K; Kamijima Y; Kao Yang YH; Kimura S; Chia-Cheng Lai E; Man KKC; Ryan P; Schuemie M; Stang P; Su CC; Wong ICK; Zhang Y; Setoguchi S
    PLoS One; 2018; 13(12):e0208796. PubMed ID: 30540837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional changes in charcoal-burning suicide rates in East/Southeast Asia from 1995 to 2011: a time trend analysis.
    Chang SS; Chen YY; Yip PS; Lee WJ; Hagihara A; Gunnell D
    PLoS Med; 2014 Apr; 11(4):e1001622. PubMed ID: 24691071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States.
    Tan X; Yang L; Khunti K; Zhang R; Zhang Y; Rajpathak S; Yu M
    Diabetes Obes Metab; 2021 Oct; 23(10):2251-2260. PubMed ID: 34132017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
    Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.
    Le Pen C; Bauduceau B; Ansolabehere X; Troubat A; Bineau S; Ripert M; Dejager S
    Ann Endocrinol (Paris); 2021 Apr; 82(2):99-106. PubMed ID: 33417963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
    Yabe D; Kuwata H; Kaneko M; Ito C; Nishikino R; Murorani K; Kurose T; Seino Y
    Diabetes Obes Metab; 2015 Apr; 17(4):430-4. PubMed ID: 25146418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan.
    Ou HT; Chang KC; Liu YM; Wu JS
    J Diabetes; 2017 Mar; 9(3):256-266. PubMed ID: 27062145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study.
    Brauer R; Wong ICK; Man KK; Pratt NL; Park RW; Cho SY; Li YJ; Iqbal U; Nguyen PA; Schuemie M
    BMJ Open; 2020 Jan; 10(1):e032426. PubMed ID: 31937652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
    Chen HH; Lin CL; Yeh SY; Kao CH
    QJM; 2016 Feb; 109(2):91-5. PubMed ID: 25991869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus.
    Stuart B; Shaffer TJ; Simoni-Wastila LJ; Zuckerman IH; Quinn CC
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):195-208. PubMed ID: 17996659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
    Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of DPP-4 inhibitors.
    Teramachi H; Ohta H; Tachi T; Toyoshima M; Mizui T; Goto C; Tsuchiya T
    Pharmazie; 2013 Nov; 68(11):909-15. PubMed ID: 24380242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.
    Flory J; Gerhard T; Stempniewicz N; Keating S; Rowan CG
    Diabetes Obes Metab; 2017 Aug; 19(8):1184-1187. PubMed ID: 28266807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, prevalence and prescription patterns of antipsychotic medications use in Asia and US: A cross-nation comparison with common data model.
    Su CC; Chia-Cheng Lai E; Kao Yang YH; Man KKC; Kubota K; Stang P; Schuemie M; Ryan P; Hardy C; Zhang Y; Kimura S; Kamijima Y; Wong ICK; Setoguchi S
    J Psychiatr Res; 2020 Dec; 131():77-84. PubMed ID: 32947205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure.
    Gokhale M; Dusetzina SB; Pate V; Chun DS; Buse JB; Stürmer T; Gower EW
    Diabetes Care; 2020 Sep; 43(9):2121-2127. PubMed ID: 32641378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes].
    Hayashi A; Kubo T; Okuyama K; Tokita S; Kamei M
    Yakugaku Zasshi; 2019; 139(12):1569-1581. PubMed ID: 31787647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Geng J; Yu H; Mao Y; Zhang P; Chen Y
    Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.